The study aims to develop novel ruthenium (Ru) compounds as antiplatelet agents, as they have been found to inhibit in vitro platelet aggregation and in vivo thrombotic platelet plug formation in mice. This suggests that Ru compounds may act as anticancer agents, as they inhibit platelet aggregation and thrombotic platelet plug formation. The study aims to characterize and check the purity of the newly synthesized ruthenium compounds, test their cytotoxicity against cancer cells, and examine their effect on extra cellular matrix (ECM) components, such as MMPs and TIMPs. The study also aims to study the regulatory machinery of Ru-mediated anticancer effects, examining the nuclear factor kappa B (NF-κB) and MAPKs pathways underlying the anticancer effect of Ru compounds. The study also aims to assay antioxidant defense systems and evaluate the impact of Ru on lung metastatic tumor nodules and histological alterations in cancer-induced mice. The proposed proposal is crucial for developing novel Ru-based MMP inhibitors, potentially leading to the development of low-cost and safe mettalo-drugs for cancer treatment.
Source
Source
science and Engineering Research Board (sERB), DsT
Pondicherry University, Kalapet, Pondicherry
Accessibility Controls